GHRS
$15.04-0.07 (-0.46%)
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate...
Recent News
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Cresco Labs Reported Q4 Revenue Growth Momentum as Margins Improved Tilray Expanded Beverage Push With $60 Million BrewDog Asset Acquisition Key Takeaways; Psychedelic Sector Helus Pharma Reported Promising Phase 2 Results for Anxiety Treatment GH Research Highlighted Strong 2025 Progress as It Prepares to Advance Its Depression Therapy Program AtaiBeckley is […]
Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on study results, FDA alignment and a DSMB recommendation. Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential HELUS PHARMA REPORTS PHASE 2 HLP004 RESULTS: Helus Pharma (HELP) announced Thursday topline results from a Phase
RBC Capital Cite GH Research PLC’s (GHRS) Long-Term Sales Potential Following Psychedelics Symposium
GH Research PLC (NASDAQ:GHRS) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. GH Research PLC (NASDAQ:GHRS) is placed sixth on our list. TheFly reported that on January 23, RBC Capital raised its price target on GHRS to $40 from $33 and maintained an Outperform rating. RBC stated that it was growing […]
Psychedelics stocks rise as Compass’ psilocybin drug heads to FDA
Shares of at least four other developers were up by mid-single digits to low-double digits at certain points on Tuesday.
How FDA’s Lifted Clinical Hold On GH001 At GH Research (GHRS) Has Changed Its Investment Story
In early January 2026, GH Research PLC reported that the FDA lifted the clinical hold on its GH001 IND, clearing the way for U.S. enrollment after Phase 2b data in treatment-resistant depression showed a meaningful placebo-adjusted improvement in MADRS scores, rapid remission rates, and a favorable safety profile with no serious treatment-related adverse events. The company also highlighted GH001’s very short median psychoactive experience of about 11 minutes, no psychotherapy requirement,...